Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Express Scripts
Boehringer Ingelheim
Johnson and Johnson
McKesson

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

OMNIPAQUE 350 Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Omnipaque 350, and when can generic versions of Omnipaque 350 launch?

Omnipaque 350 is a drug marketed by Ge Healthcare and is included in two NDAs.

The generic ingredient in OMNIPAQUE 350 is iohexol. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the iohexol profile page.

Summary for OMNIPAQUE 350
Drug patent expirations by year for OMNIPAQUE 350
Recent Clinical Trials for OMNIPAQUE 350

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute (NCI)N/A
University of North Carolina, Chapel HillEarly Phase 1
Duke Clinical Research InstitutePhase 4

See all OMNIPAQUE 350 clinical trials

Pharmacology for OMNIPAQUE 350

US Patents and Regulatory Information for OMNIPAQUE 350

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare OMNIPAQUE 350 iohexol SOLUTION;INJECTION, ORAL 018956-004 Dec 26, 1985 RX Yes Yes   Start Trial   Start Trial   Start Trial
Ge Healthcare OMNIPAQUE 350 iohexol SOLUTION;INJECTION, ORAL 020608-003 Oct 24, 1995 RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for OMNIPAQUE 350

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge Healthcare OMNIPAQUE 350 iohexol SOLUTION;INJECTION, ORAL 018956-004 Dec 26, 1985   Start Trial   Start Trial
Ge Healthcare OMNIPAQUE 350 iohexol SOLUTION;INJECTION, ORAL 018956-004 Dec 26, 1985   Start Trial   Start Trial
Ge Healthcare OMNIPAQUE 350 iohexol SOLUTION;INJECTION, ORAL 018956-004 Dec 26, 1985   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Dow
Moodys
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.